help button home button Am J Pathol R & D Systems
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Altavilla, G.
Right arrow Articles by Corallini, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Altavilla, G.
Right arrow Articles by Corallini, A.
(American Journal of Pathology. 2000;157:1081-1089.)
© 2000 American Society for Investigative Pathology

Short Communications

Enhancement of Chemical Hepatocarcinogenesis by the HIV-1 tat Gene

Giuseppe Altavilla*, Antonella Caputo{dagger}, Massimo Lanfredi{dagger}, Catia Piola{ddagger}, Giuseppe Barbanti-Brodano{dagger} and Alfredo Corallini{dagger}

From the Institute of Pathologic Anatomy and Histology,*
University of Padova, Padova; the Department of Experimental and Diagnostic Medicine,{dagger}
Section of Microbiology and the Interdepartment Centre for Biotechnology,{ddagger}
University of Ferrara, Ferrara, Italy

The human immunodeficiency virus-1 Tat protein is suspected to be involved in the neoplastic pathology arising in AIDS patients. tat-transgenic (TT) mice, which constitutively express Tat in the liver, develop liver cell dysplasia (LCD) that may represent a preneoplastic lesion. To test if TT mice are predisposed to liver carcinogenesis, we treated them with diethylnitrosamine, a hepatotropic carcinogen. Diethylnitrosamine-treated TT mice developed both preneoplastic and neoplastic lesions in the liver. They showed an enhancement of LCD and developed basophilic liver cell nodules (BLCN), hepatocellular adenomas (HA), and hepatocellular carcinomas (HC). Both preneoplastic (LCD and BLCN) and neoplastic (HA and HC) lesions were significantly more frequent in TT than in control mice: 29.7% versus 12.7% for LCD, 57.9% versus 23.3% for BLCN, 40.6% versus 10.0% for HA, and 50.0% versus 12.7% for HC. These results indicate that Tat expression in the liver predisposes to both initiation of hepatocarcinogenesis and to malignant progression of liver tumors. This study supports a role for Tat in enhancing the effect of endogenous and exogenous carcinogens in human immunodeficiency virus-1-infected patients, thereby contributing to tumorigenesis in the course of AIDS.




This article has been cited by other articles:


Home page
 JCOHome page
F. Di Benedetto, N. De Ruvo, M. Berretta, M. Masetti, R. Montalti, S. Di Sandro, C. Quintini, M. Codeluppi, U. Tirelli, and G. E. Gerunda
Don't Deny Liver Transplantation to HIV Patients With Hepatocellular Carcinoma in the Highly Active Antiretroviral Therapy Era
J. Clin. Oncol., May 10, 2006; 24(14): e26 - e27.
[Full Text] [PDF]

Home page
 Toxicol SciHome page
J. E. Aldridge, J. A. Gibbons, M. M. Flaherty, M. L. Kreider, J. A. Romano, and E. D. Levin
Heterogeneity of Toxicant Response: Sources of Human Variability
Toxicol. Sci., November 1, 2003; 76(1): 3 - 20.
[Abstract] [Full Text] [PDF]

Home page
 Annals of Clinical & Laboratory ScienceHome page
R. B. Birrer, D. Birrer, and J. V. Klavins
Hepatocellular Carcinoma and Hepatitis Virus
Ann. Clin. Lab. Sci., January 1, 2003; 33(1): 39 - 54.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Society for Investigative Pathology.